PA
GLUE icon

Profund Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Profund Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$729K Sell
30,111
-16,573
-36% -$313K 0.02% 429
2026
Q1 		$768K Buy
46,684
+21,465
+85% +$410K 0.03% 420
2025
Q4 		$395K Buy
+25,219
New +$340K 0.01% 692

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Profund Advisors's GLUE Position: Q2 2026 in Review

Profund Advisors reduced its Monte Rosa Therapeutics (GLUE) stake by 36% in Q2 2026, selling an estimated $313K and leaving 30,111 shares worth $729K. The position accounts for 0.02% of the portfolio, ranked #429.

Profund Advisors first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. The position peaked at $768K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Profund Advisors held 30,111 shares of Monte Rosa Therapeutics worth $729K as of Q2 2026.
  • Profund Advisors sold 16,573 Monte Rosa Therapeutics shares in Q2 2026, an estimated $313K.
  • Monte Rosa Therapeutics made up 0.02% of Profund Advisors's portfolio in Q2 2026, its #429 holding.
  • Profund Advisors first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Profund Advisors's Monte Rosa Therapeutics position peaked at $768K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.